APA (7th ed.) Citation

Kenealy, M., Benson, W., Stevenson, W., Eek, R., Zantomio, D., Cunningham, I., . . . Seymour, J. (2015). 13 THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL. Leukemia Research, 39, S5. https://doi.org/10.1016/S0145-2126(15)30014-X

Chicago Style (17th ed.) Citation

Kenealy, M., et al. "13 THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL." Leukemia Research 39 (2015): S5. https://doi.org/10.1016/S0145-2126(15)30014-X.

MLA (9th ed.) Citation

Kenealy, M., et al. "13 THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL." Leukemia Research, vol. 39, 2015, p. S5, https://doi.org/10.1016/S0145-2126(15)30014-X.